Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.
about
Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP poolPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationStructure-based design and mechanisms of allosteric inhibitors for mitochondrial branched-chain α-ketoacid dehydrogenase kinase.The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomesA new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data.Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance.Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.Modeling kinetic data from in vitro drug metabolism enzyme experiments.The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentPrediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CA Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidationAn Automated High-Throughput Metabolic Stability Assay Using an Integrated High-Resolution Accurate Mass Method and Automated Data Analysis Software1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain.In vitro evaluation of hepatic and extra-hepatic metabolism of coumarins using rat subcellular fractions: correlation of in vitro clearance with in vivo data.Prediction of hepatic clearance in human from in vitro data for successful drug development.Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometryMetabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes.Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic ClearanceStereoselective biotransformation of ketamine in equine liver and lung microsomes.Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid.Determination of metabolic profile of anti-malarial trioxane CDRI 99/411 in rat liver microsomes using HPLC.An integrated drug-likeness study for bicyclic privileged structures: from physicochemical properties to in vitro ADME properties.In vitro glucuronidation of 2,2-bis(bromomethyl)-1,3-propanediol by microsomes and hepatocytes from rats and humansA commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development.N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activityPharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human.Crucial role of mechanisms and modes of toxic action for understanding tissue residue toxicity and internal effect concentrations of organic chemicals.A pharmacokinetic model of cis- and trans-permethrin disposition in rats and humans with aggregate exposure application.Assessment of drug-drug interactions: concepts and approaches.Optimization of metabolic stability as a goal of modern drug design.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosisUse of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liverPredicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Interactions of herbs with cytochrome P450.Toward modular biological models: defining analog modules based on referent physiological mechanisms.
P2860
Q27334876-833379E3-F50E-4BF2-A83A-E756A8C18BD8Q27643976-8261B924-1C92-4B6A-86F9-8EC2BD5746D7Q28088352-E8668DED-242E-4BB6-8F58-EE484278871CQ28291558-5F4CBF79-B567-42F1-9817-EDB128F0E7ACQ28365923-EB52083C-60D5-42B5-9EF3-E6A3F0FA96CFQ30577525-AF11C1CE-AB9A-4638-BCFE-AEA63766DE0DQ30593578-57549F95-215D-4011-A637-1D4CB37E2CD5Q30763235-62014B23-B06E-43F0-97D2-AA842E05D644Q30941529-D3A710A4-6A23-4302-BF88-794CF3900C93Q30977143-133E15B8-6DBC-4BCA-A179-D965C7AEDAA7Q30981419-F9510DDA-8AE9-462B-BD06-D3620F282DC4Q30985909-6518D8EA-21D3-467E-88FF-C6D8F6C7BCBBQ31034463-37490C73-6324-4A58-8D50-BA21742DD238Q31114750-93A14BCF-C6E4-46C3-9607-D0066077138AQ31170459-394AFCB9-ECBC-4D1A-A857-C7630C0F9333Q33423100-95248939-3078-496D-95CD-D92A55959467Q33437736-C5064D14-8B43-4725-A169-D9DAF9A4BE5CQ33519666-798FB057-AFF8-4A04-BD42-99536F222A49Q33555599-82768E82-C546-4006-9B8A-79AC53271596Q33566159-3151FAF1-96BC-490E-825A-FB4969B12DA1Q33588394-F0775B3B-AEBA-4AAA-BE94-3B2702BB0CEEQ33651967-E3A51DCD-AF3B-4B44-920A-4598E05DDF88Q33693946-419AEFFF-7BB8-4A34-AC5B-B0851442AC18Q33876677-E3298ABC-6A46-42B7-90FD-011F5611DE7AQ33888168-367780DF-A32B-4C65-81F2-6EAB14C12AEFQ33891027-DD6EB67C-257E-4488-847E-EFD6D4A5EB19Q33896258-67698305-2390-4477-8DE8-E40A0A23BDEFQ34113382-9C3178CC-6B6D-4194-BDB3-F19EDF1BCB51Q34137634-75379F6C-009A-4164-A058-339C5418A06AQ34156521-F2B766E5-5018-4B12-8397-4760D6CB7786Q34292023-7C403F01-D70A-4352-AD02-1EE2A42173C8Q34378923-EB1FD6E0-7AF5-4335-A245-13F55B980D53Q34386836-52FB2A64-04C2-4256-9FDD-9B1856E3169CQ34430456-FEC10B9E-7F23-46E5-80C9-657FC94BDBE9Q34459374-0BD1CAF0-419A-4A18-83FF-64337A466CBBQ34503553-C0B29087-D3B9-491D-AB3D-4E2AA01D0BE4Q34857030-A23E93D8-EA74-4E84-9E25-BD6191EF822EQ35027930-4C01A21B-23D1-4C04-B93A-AB761ACC6BE6Q35085032-14205BD2-5FBD-4C08-B70D-F4FACD0BC507Q35225033-B499DF97-5FA4-4EAE-BF60-1FF7FAE83358
P2860
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.
@en
type
label
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.
@en
prefLabel
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.
@en
P1476
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.
@en
P2093
Houston JB
P304
P356
10.1016/0006-2952(94)90520-7
P407
P577
1994-04-01T00:00:00Z